Rapid Pathogen Screening Secures $6.25 Million Additional Funding
Rapid Pathogen Screening,Inc. (RPS®), an emerging manufacturer in point-of-care (POC)
diagnostic testing, has secured a $6.25 million investment. Funds will be used to accelerate the growth of the company´s product development pipeline and to facilitate the continued commercial success of its existing products, the AdenoPlus® test to support the rapid diagnosis of Adenoviral conjunctivitis (pink eye) and InflammaDry for inflammatory dry eye disease.
RPS is strategically focused on utilizing its unique, patented technology platform to design, develop, and deliver a variety of novel and cost-effective point-of-care tests for infectious diseases and inflammatory conditions.
As a result of U.S. government contracts, this platform is also being developed to help detect the body´s immune response to viral and bacterial infections as well as chemical nerve agent blood toxins. RPS tests allow healthcare providers to more accurately diagnose diseases, provide appropriate and timely treatment, and reduce the healthcare costs associated with spread of disease and unnecessary treatment methods.
Tags: Toxins, Pathogen, Point of Care
Date Published: August 6, 2013
Source article link: Rapid Pathogen Screening » company contact details
GC and CFU Correlation Of 9 Mycoplasma spp Examined With Sartorius' Microsart® Range
Why Bio-Rad? Learn More Here!
What's Holding Up Field-based Pathogen Detection - White Paper
Mérieux NutriSciences - European Food Safety Trends, Key Issues & Perspectives
How to Prevent False-Positive Results in Pathogen Testing